1997-2001: Bachelor in Chemistry, Nanchang University
2001-2006: PhD in Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Supervisor: Nan Fajun
2006-2009: Postdoctoral Research in Medicinal Chemistry, University of Illinois at Chicago, Collaborative Supervisor: Alan P. Kozikowski
2022.12-present: Professor, Doctoral Supervisor, Key Laboratory of Regulatory Biology, East China Normal University
2015.12-2022.12: Researcher, Doctoral Supervisor, Key Laboratory of Regulatory Biology, East China Normal University
2009.12-2015.12: Associate Professor, Key Laboratory of Regulatory Biology, East China Normal University
18th Chinese Pharmaceutical Association - Servier Young Medicinal Chemist Award (2015)
Excellent Mentor in the 6th China International 'Internet+' College Students Innovation and Entrepreneurship Competition, Shanghai Division (2020)
Research
Chemical Biology Medicinal Chemistry Targeting Key Transcription Factors in Antitumor Pharmacology
Discovery of a Potent and Oral Complex I OXPHOS Inhibitor that Abrogates Tumor Growth and Circumvents MEKi Resistance, Yihua Chen et al., 2023
Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer, Yihua Chen et al., 2023
Discovery of a Highly Potent and Selective MYOF Inhibitor with Improved Water Solubility for the Treatment of Gastric Cancer, Yihua Chen et al., 2023
Current Advances of Small Molecule E3 Ligands for Proteolysis-Targeting Chimeras Design, Yihua Chen et al., 2023
A novel methuosis inducer DZ-514 possesses antitumor activity via activation of ROS-MKK4-p38 axis in triple negative breast cancer, Yihua Chen et al., 2023
Selectively targeting STAT3 using a small molecule inhibitor is a potential therapeutic strategy for pancreatic cancer, Yihua Chen et al., 2023
Discovery of YH677 as a cancer stemness inhibitor for suppressing triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway, Yihua Chen et al., 2023
Small-Molecule Modulators Targeting SHP2 for Cancer Therapy, Yihua Chen et al., 2023
Recent advances in small molecule and peptide inhibitors of glucose-regulated protein 78 for cancer therapy, Yihua Chen et al., 2023
A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia, Yihua Chen et al., 2023
Preclinical characterization of WB737, a potent and selective STAT3 inhibitor, in natural killer/T-cell lymphoma, Yihua Chen et al., 2023
Targeting Key Proteins involved in Transcriptional Regulation for Cancer Therapy: Current Strategies and Future Prospective, Yihua Chen et al., 2022
Discovery of 2-Amino-3-cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis, Yihua Chen et al., 2022
Discovery of a Novel Potent STAT3 Inhibitor HP590 with Dual p-Tyr705/Ser727 Inhibitory Activity for Gastric Cancer Treatment, Yihua Chen et al., 2022
Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer treatment, Yihua Chen et al., 2022
B‑cell lymphoma 6 inhibitors: current advances and prospects of drug development for diffuse large B-cell lymphomas, Yihua Chen et al., 2022
An instructive attempt on developing aptamer-constructed PROTAC for potential breast cancer treatment, Yihua Chen et al., 2022
Discovery of 1,5-diaryl-1,2,4-triazole derivatives as MYOF inhibitors and its antitumor effects in pancreatic cancer, Yihua Chen et al., 2022
Novel ortho-diphenyl-five-member N-hetero- aromatics compounds as potent anti-cancer cell agents, Yihua Chen et al., 2022
The promising combination therapy strategy for overcoming resistance to histone deacetylase inhibitors in diffuse large B-cell lymphoma, Yihua Chen et al., 2022
An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo, Yihua Chen et al., 2022
A potent and selective small molecule inhibitor of myoferlin attenuates colorectal cancer progression, Yihua Chen et al., 2021
Targeting Pyruvate Carboxylase by a Small Molecule Suppresses Cancer Progression, Yihua Chen et al., 2020
In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15, Yihua Chen et al., 2020
Synthesis and Biological Evaluation of B‑Cell Lymphoma 6 Inhibitors of N-phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth, Yihua Chen et al., 2020
Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma, Yihua Chen et al., 2020
Design, synthesis and evaluation of phenylthiazole and phenylthiophene pyrimidindiamine derivatives targeting the bacterial membrane, Yihua Chen et al., 2020
Synthesis and Biological Evaluation of Novel Thiophene-based N-bis-substituted Aromatic Amide Hydroxamic Acid Derivatives as Histone Deacetylase Inhibitors with Antitumor Activities, Yihua Chen et al., 2020
An Emerging Therapeutic Approach by Targeting Myoferlin (MYOF) for Malignant Tumors, Yihua Chen et al., 2020
Research on Function and Mechanisms of a Novel Small Molecule WG449E for Hypertrophic Scar, Yihua Chen et al., 2020
Modification and Biological Evaluation of a Series of 1,5-Diaryl-1,2,4-triazole Compounds as Novel Agents against Pancreatic Cancer Metastasis through Targeting Myoferlin, Yihua Chen et al., 2019
Design, synthesis and evaluation of hybrid of tetrahydrocarbazole with 2,4-diaminopyrimidine scaffold as antibacterial agents, Yihua Chen et al., 2019
Discovery of Potent Ureido Tetrahydrocarbazole Derivatives for Cancer Treatments through targeting Tumor-associated Macrophages, Yihua Chen et al., 2019
Small Molecule PROTACs: An Emerging Technology for Targeted Therapy in Drug Discovery, Yihua Chen et al., 2019
Recent Advances of Small Molecular Regulators Targeting G Protein-Coupled Receptors Family for Oncology Immunotherapy, Yihua Chen et al., 2019
Next-Generation of Selective Histone Deacetylase Inhibitors, Yihua Chen et al., 2019
Development of Hydroxamate-Based Histone Deacetylase Inhibitors of Bis-substituted Aromatic Amides with Antitumor Activities, Yihua Chen et al., 2019
Inhibition of CDC25B with WG-391D impedes the tumorigenesis of ovarian cancer, Yihua Chen et al., 2019
A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer, Yihua Chen et al., 2018
Inhibition of HDACs-EphA2 signaling Axis with WW437 demonstrates promising preclinical antitumor activity in breast cancer, Yihua Chen et al., 2018
Keywords
Chemical BiologyMedicinal ChemistryTranscription FactorsAntitumorPharmacologyDrug DesignCancer TherapyMolecular InhibitorsSmall MoleculesTargeted Therapy
Area of Focus
Chemical Biology | Medicinal Chemistry | Transcription Factors | Antitumor | Pharmacology | Drug Design | Cancer Therapy | Molecular Inhibitors | Small Molecules | Targeted Therapy
